Recent developments in bioengineering and organic chemistry have enabled targeting of the previously ‘undruggable’ KRAS; this review summarizes the successes, challenges and future of KRAS therapeutics in the clinic.
- Anupriya Singhal
- Bob T. Li
- Eileen M. O’Reilly